China-based Innocare Pharma announced that its Phase III trial of fadeucravacitinib, an experimental treatment for moderate-to-severe plaque psoriasis, has met its primary endpoint.
The company plans to advance the regulatory filing process for fadeucravacitinib (ICP-488) following the completion of the study.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
Close to home. Always in the loop.
A low-commitment monthly bundle that keeps your business in front of local audiences across HyperLocal Loop and the OBBM Network.
Every Patriot Package is priced at over 40% off standard AdRevv list rates — and the discount deepens as you scale, up to 60% off at the Enterprise tier.
Need a custom configuration? Build your own package →
Add the app to your home screen for a faster, full-screen experience.
